David D. Meek Sells 2,112 Shares of uniQure N.V. (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director David D. Meek sold 2,112 shares of the business’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director now owns 34,190 shares of the company’s stock, valued at $494,045.50. This trade represents a 5.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

uniQure Stock Performance

QURE stock opened at $14.33 on Thursday. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53. The firm has a market cap of $785.00 million, a PE ratio of -3.26 and a beta of 0.08. The business has a 50 day moving average of $14.48 and a 200-day moving average of $13.99. uniQure N.V. has a 12-month low of $3.73 and a 12-month high of $19.18.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. The firm had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. As a group, sell-side analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

QURE has been the subject of several recent research reports. Wells Fargo & Company decreased their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research report on Friday, February 28th. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Chardan Capital reissued a “buy” rating and issued a $38.00 price objective on shares of uniQure in a research note on Friday, May 30th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. Finally, Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.82.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Tudor Investment Corp ET AL grew its position in uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 1,371 shares during the period. Wells Fargo & Company MN boosted its stake in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. Northern Trust Corp boosted its stake in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after acquiring an additional 3,996 shares during the period. Finally, Twin Tree Management LP purchased a new stake in shares of uniQure during the 4th quarter worth approximately $77,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.